Print Page     Close Window     

Investor snapshot

Company Profile
Nexvet Biopharma public limited company and its subsidiaries (the “Company”) is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing novel, species-specific biologics. Biologics are therapeutic proteins derived from biological sources. As a class, biologics have transformed human medicine in recent decades and represent many of the top-selling therapies on the market today. The Company’s platform technology, which it refers to as “PETization,” is an algorithmic approach that enables the Company to rapidly create monoclonal antibodies (“mAbs”) a type of biologic, that are designed to be recognized as “self” or “native” by an animal’s immune system, a property referred to as “100% species-specificity.” PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to cre... more >
Recent Newsmore >
DateTitle
16 June 2017Nexvet Biopharma plc ("Nexvet") Rule 15 Announcement
DUBLIN, Ireland, June 16, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED INDIRECT SUBSIDIARY OF ZOETIS INC. of NEXVET BIOPHARMA PUBLIC LIMITED COMPANY to be implemented by means of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to dispatch of Rule 15 Letter On April 13, 2017, Nexvet Biopharma plc, a public limited ... 
14 June 2017Nexvet Biopharma plc ("Nexvet") Rule 2.10 Announcement
DUBLIN, Ireland, June 19, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following; In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover Rules, 2013 (the "Irish Takeover Rules"), Nexvet confirms that as at close of business on June 16, 2017 its issued share capital comprised 11,922,150 ordinary shares of $0.125 each (the “Ordinary Shares”). The Ordinary Shares are admitted to trading on NASDAQ under the ticker symbol NVET. The Internationa... 
07 June 2017Nexvet Biopharma plc ("Nexvet") Rule 17(b) Announcement
DUBLIN, Ireland, June 07, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED INDIRECT SUBSIDIARY OF ZOETIS INC. of NEXVET BIOPHARMA PUBLIC LIMITED COMPANY to be implemented by means of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and EGM On April 13... 
02 June 2017Nexvet Biopharma plc ("Nexvet") Rule 17 Announcement
DUBLIN, Ireland, June 02, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED INDIRECT SUBSIDIARY OF ZOETIS INC. of NEXVET BIOPHARMA PUBLIC LIMITED COMPANY to be implemented by means of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to convening of Scheme Meeting On April 13, 2017, Nexvet Biopharma plc, a public limited ... 
Featured Items
Download Documentation Nexvet Cowen Health Care Conference Corporate Overview
Stock Quotemore >
NVET (ADS)
Exchange :NASDAQ
Price :$6.67
Change :0.00 (0.00%)
Volume :13,207
Data as of 06/27/17 11:05 a.m. ET
Minimum 20 minute delay
Receive Email AlertsE-mail Alert Icon
Sign up to receive email alerts whenever Nexvet Biopharma plc posts new information to the site. Just enter your email address and click Submit.
 


Data Provided by Thomson Reuters

Copyright © NEXVET. All Rights Reserved.